New Rapid Test Changes Brain Tumour Diagnosis

A major breakthrough in medical technology is set to change how doctors treat brain tumours. According to The Guardian Health, a new rapid test can now identify the type of brain cancer while a patient is still in the operating room. This development is being described by scientists as a "gamechanger" that could help patients who do not have much time to wait for answers.

In the past, patients often had to wait up to eight weeks to receive a diagnosis after a biopsy, which is a procedure where a small piece of tissue is removed for testing. This long waiting period can be very difficult for patients and their families. The new method, developed by the Brain Tumour Research Centre of Excellence at the University of Nottingham, reduces this waiting time to just two hours. By providing results while the patient is still on the operating table, surgeons can make better decisions about the next steps of care immediately.

This new tool is a genomic test. This means it looks at the genetic code—the set of instructions inside living cells—of a tumour sample. According to The Guardian Health, the process involves taking a small piece of tissue from the tumour and placing it into a special machine about the size of a shoebox. This machine, made by Oxford Nanopore, uses a tiny hole called a nanopore to read the DNA molecules. This process reveals the unique genetic makeup of the tumour, which tells doctors exactly what kind of cancer they are dealing with.

Prof Frankie Swords, the medical director for the NHS, stated that this rapid test is a "huge leap forward" for patients. She noted that it has the potential to completely change the way brain tumours are diagnosed. Because the test is so fast, patients can start their treatment much sooner than before. This is especially important because primary brain tumours are the leading cause of cancer deaths in children and adults under the age of 40 in the UK. Starting treatment early can be the difference between life and death for many people.

Stuart Smith, a consultant neurosurgeon at Nottingham University Hospitals NHS Trust, played a key role in creating this technology. He explained that having detailed information about a tumour while a patient is still in surgery is a major improvement. Before this, doctors had to look at samples under a microscope, which was slower and sometimes less accurate. With the new genomic test, doctors can get results that are both faster and more precise.

Currently, the NHS has begun using this tool in five specialist centres. These include Nottingham University Hospitals, University Hospitals Birmingham, Great Ormond Street Hospital, King’s College Hospital, and Newcastle Hospitals. These centres are part of a pilot program, which is a small-scale trial used to test how well a new system works before it is used everywhere. After this initial phase, the NHS plans to bring the technology to other hospitals in cities including Bristol, Oxford, Leeds, and Manchester.

Beyond just faster surgery, this technology could also help patients get early access to clinical trials. Clinical trials are research studies that test new medical treatments to see if they are safe and effective. By identifying the specific type of tumour quickly, doctors can see if a patient is a good fit for a new, experimental medicine. This gives patients more options when standard treatments might not be enough.

Overall, the introduction of this rapid test represents a significant step forward in cancer care. By removing the uncertainty of long wait times, the medical community hopes to provide better, faster, and more targeted care for those facing a brain tumour diagnosis. As the NHS rolls out this technology to more hospitals, the hope is that many more patients will benefit from these faster results, ultimately leading to better health outcomes across the country.